Developing Innovative Peptides

November 2020

plc

• Listed on UK AIM (LSE:IMM) & Euronext Growth Brussels (ALIMM)

• Pipeline of innovative peptide products

• Portfolio from early to late stage

• Lupuzor™ - lead product for Lupus - optimised Phase III international trial

• US partner ‘Avion’ signed in Q4 2019 -funding Lupus trial • Milestones up to $70m & tiered double-digit royalties

up to 17%

• Discovery labs in France

• Shares in issue: 250,221,297 (as of 27/11/20)

ImmuPharma

2

4 Therapy Areas | 2 Late Stage Assets

1

‘Lupuzor™ for Lupus’

2

‘BioAMP-B anti-fungal’

3

Lupuzor™ for Lupus Lupus

• Autoimmune chronic inflammatory disease

• Unmet market need - lack of safe and effective treatments

• Multi-billion sales potential

• Patients*: >5m globally | 1.5m lupus sufferers in EU/US/Japan

• GSK’s approval of Benlysta in 2011 paves the path to market

Lupuzor™

• Novel mechanism that modulates (not blocks) immune system

• Outstanding safety profile

Attractive economics

• Lupus patients treated by specialists = low marketing costs

• Benlysta priced at approx. US$40,000 / per patient / per year

• Lupuzor™ anticipated to have competitive pricing with higher margins

* source: Lupus Foundation of America ‘www.lupus.org’ (2019)4

Avion partnership delivering on Lupuzor™

• New ‘optimized’ international Phase III trial in Lupus finalised

• Phase III study development team includes 6KOLS, Avion and ImmuPharma

• SPA* submission to FDA

• Target to commence Phase III at earliest opportunity post FDA guidance

• New Phase III fully funded by Avion with attractive milestone payments and royalties on future sales

• Discussions continue with potential partners for Lupuzor™ in Lupus outside of US

*SPA is a process in which sponsors reach agreement with the FDA on the design and size of clinical trials such that they adequately address scientific and regulatory requirements for a study that could support marketing approval.

HQ: Georgia USA with >200 employees Fully integrated in drug development,

sales and marketing Focus on Rheumatology, Neurology,

Endocrine and Women’s Health Annual sales >$250m, strong growth

(50% pa) Strong balance sheet, well funded Focus on low competition / high margin

branded opportunities Sustained pipeline of new opportunities

5

BioAMP-B - Anti-fungal opportunity

• BioAMP-B is a novel peptide-based drug that offers potential improvement on Amphotericin-B (“Amp-B”)

• Amp-B one of the few effective treatments for serious and life threatening fungal infections such as aspergillosis (lung infection)

• Leading AMP-B, ‘Ambisome’** causes serious kidney toxicity in c.15% of patients – adverse events in >20%

• BioAMP-B’s target profile is to achieve superior safety profile to Ambisome

• Sales of Ambisome in 2019 were $407m (p.a.)

• Next steps: • Bio equivalence study, with potential market launch date in 2022• Partnering opportunities – attractive given need for new

antifungals in ‘late stage development

*The World Health Organisation** Data from Ambisome prescribing information*** Gilead financial data6

Investment summary

• Robust balance sheet• Following recent successful £6.5m placing• Cash runway until end 2023

• Lupuzor™ fully funded by US partner Avion• Moving into optimised Phase III intl. trial

• BioAMP-B moving to bioequivalence status• Licensing opportunities

• Near term inflexion points• Continued strong news flow

• Partnering opportunities• Lupuzor™ in key territories outside of US• BioAMP-B - globally

7

ImmuPharma PLCPlease contact us on:

Dimitri Dimitriou, Chief Executive Officer dimitri.dimitrou@immupharma.com

Lisa Baderoon, Head of Investor Relationslisa.baderoon@immupharma.comorinvestors@immupharma.com

Tel: +44 (0) 20 7152 4080M: +44 (0) 7721 413 496

www.immupharma.co.uk

8

9